Voyager Therapeutics (VYGR) Other Accumulated Expenses (2016 - 2024)
Historic Other Accumulated Expenses for Voyager Therapeutics (VYGR) over the last 10 years, with Q3 2024 value amounting to $7.0 million.
- Voyager Therapeutics' Other Accumulated Expenses rose 12469.41% to $7.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $7.0 million, marking a year-over-year increase of 12469.41%. This contributed to the annual value of $3.2 million for FY2023, which is 1299.44% up from last year.
- Per Voyager Therapeutics' latest filing, its Other Accumulated Expenses stood at $7.0 million for Q3 2024, which was up 12469.41% from $6.7 million recorded in Q2 2024.
- In the past 5 years, Voyager Therapeutics' Other Accumulated Expenses registered a high of $7.0 million during Q3 2024, and its lowest value of $2.5 million during Q2 2022.
- Over the past 5 years, Voyager Therapeutics' median Other Accumulated Expenses value was $3.5 million (recorded in 2020), while the average stood at $4.2 million.
- As far as peak fluctuations go, Voyager Therapeutics' Other Accumulated Expenses tumbled by 4916.53% in 2022, and later surged by 12469.41% in 2024.
- Voyager Therapeutics' Other Accumulated Expenses (Quarter) stood at $4.2 million in 2020, then skyrocketed by 32.71% to $5.6 million in 2021, then crashed by 49.17% to $2.8 million in 2022, then increased by 12.99% to $3.2 million in 2023, then skyrocketed by 118.09% to $7.0 million in 2024.
- Its last three reported values are $7.0 million in Q3 2024, $6.7 million for Q2 2024, and $5.9 million during Q1 2024.